

## Notification of Expiry of NUZOA Listed Options

**20 March 2026 – Melbourne Australia:** Neurizon® Therapeutics Limited (ASX:NUZ & NUZOA; OTCQB:NUZTF) ("Neurizon" or "the Company"), a clinical-stage biotech company dedicated to advancing innovative treatments for neurodegenerative diseases, advises that the attached letter is being sent to registered holders of the Company's listed NUZOA options (ASX: NUZOA; "NUZOA Listed Options").

The NUZOA Listed Options are exercisable at \$0.15 (15 cents) each and will expire at 5.00pm (AEST) on Thursday, 30 April 2026 ("Expiry Date").

Official quotation of NUZOA on ASX will cease at the close of trading on Friday, 24 April 2026, being four business days before the Expiry Date.

If payment for the exercise of NUZOA Listed Options is not received by 5:00pm (AEST) on Thursday, 30 April 2026, the options will lapse and all rights under the options will cease at that time.

The attached letter outlines the courses of action available to holders of these soon-to-expire NUZOA Listed Options.

-ENDS-

This announcement is authorized for release by the Board of Directors of Neurizon Therapeutics Limited.

For further information, please contact:

**Neurizon Therapeutics**

Lidija Damjanovic  
Marketing & Corporate Affairs  
Email: [lidija@neurizon.com](mailto:lidija@neurizon.com)  
Phone: +61 (0) 425 700 504

**Australia Investor Relations**

Henry Jordan  
Six Degrees Investor Relations  
Email: [henry.jordan@sdir.com.au](mailto:henry.jordan@sdir.com.au)  
Phone: +61 (0) 431 271 538

**U.S. Investor Relations**

Matthew Selinger  
Integrous Communications  
Email: [mselinger@integcom.us](mailto:mselinger@integcom.us)  
Phone: +1 415-572-8152

### About Neurizon Therapeutics Limited

Neurizon Therapeutics Limited (ASX: NUZ) is a clinical-stage biotechnology company dedicated to advancing treatments for neurodegenerative diseases. Neurizon is developing its lead drug candidate, NUZ-001, for the treatment of ALS, which is the most common form of motor neurone disease. Neurizon's strategy is to accelerate access to effective ALS treatments for patients while exploring the potential of NUZ-001 for broader neurodegenerative applications. Through international collaborations and rigorous clinical programs, Neurizon is dedicated to creating new horizons for patients and families impacted by complex neural disorders. NUZ-001 is an investigational product and is not approved for commercial use in any jurisdiction.

### Neurizon Investor Hub

We encourage you to utilise our Investor Hub for any enquiries regarding this announcement or other aspects concerning Neurizon. This platform offers an opportunity to submit questions, share comments, and view video summaries of key announcements.

To access Neurizon Investor Hub please scan the QR code or visit <https://investorhub.neurizon.com>



Neurizon® is a registered trademark of Neurizon Therapeutics Limited

20 March 2026

Dear Option Holder,

## **EXPIRY OF NUZOA LISTED OPTIONS (ASX:NUZOA)**

We are writing to you as a registered holder of NUZOA listed options (ASX:NUZOA) in Neurizon Therapeutics Limited (**Company**) to remind you that the options will expire at 5:00pm (AEST) on Thursday, 30 April 2026 (**Expiry Date**).

Each NUZOA listed option entitles you to subscribe for one fully paid ordinary share in the Company upon payment of \$0.15 (15 cents) per option.

Your option holding may be exercised in whole or in part by payment of \$0.15 (15 cents) for each option exercised, provided that payment is received no later than 5:00pm (AEST) on Thursday, 30 April 2026.

If payment is not received by 5:00pm (AEST) on Thursday, 30 April 2026, the options will lapse and all rights under the options will cease at that time.

### **Courses of Action Available to You**

As a holder of NUZOA listed options, you may:

- a) Exercise the options on or before 5:00pm (AEST) on Thursday, 30 April 2026;
- b) Sell your options on the Australian Securities Exchange (**ASX**). Official quotation of NUZOA will cease at the close of trading on Friday, 24 April 2026; or
- c) Do nothing. If you do not exercise or sell your options, they will expire at 5:00pm (AEST) on Thursday, 30 April 2026 and your right to subscribe for ordinary shares at \$0.15 (15 cents) per share will lapse.

There is no obligation on option holders to exercise their options. However, under paragraph 5.2 of Appendix 6A of the ASX Listing Rules, the Company is required to advise option holders of the information contained in this notice.

### **Market Information**

The market sale price of ordinary shares in Neurizon Therapeutics Limited on ASX was \$0.084 (8.4 cents) on Thursday, 19 March 2026, being the last trading day prior to the date of this notice.

During the three (3) months preceding the date of this notice:

- the highest market sale price of ordinary shares on ASX was \$0.105 (10.5 cents) on 12 March 2026; and
- the lowest market sale price of ordinary shares on ASX was \$0.076 (7.6 cents) on 17 March 2026.

### **Exercise Instructions**

If you wish to exercise your options, you must complete the instructions set out on your “Notice of Exercise of Options” form enclosed with this notice. Please ensure a payment of \$0.15 (15 cents) per option exercised is received by the Company’s share registry no later than 5:00pm (AEST) on Thursday, 30 April 2026.

This letter does not constitute financial product advice. If you are in any doubt as to what you should do, you should consult your professional adviser.

If you have any questions, please do not hesitate to contact the Company's share registry, Automic, via telephone on 1300 288 664 (within Australia) or +61 2 9698 5414 (international) between 8.30am and 7.00pm (Sydney time), Monday to Friday or by email at [corporate.actions@automicgroup.com.au](mailto:corporate.actions@automicgroup.com.au).

Yours faithfully,



Stefan Ross  
Company Secretary  
Neurizon Therapeutics Limited

SRN/HIN:

Security Code: NUZOA

Number of Options held as at :

Option Expiry Date: 30 April 2026

Exercise Price: A\$0.15

Total amount payable (exercising in full):

## Notice of Exercise of Options

To exercise your Options please follow the instructions set out on this form. You do not need to return this form when making a payment by BPAY® or Electronic Funds Transfer (EFT).

I/we hereby exercise the following number of options and make payment in Australian currency for the amount payable. Please issue me/us Ordinary Shares calculated on the basis of one Ordinary Share for every one Option which I/we exercise. You agree to accept such Shares subject to the Constitution of Neurizon Therapeutics Limited.

### 1. Number of Options to be Exercised

,    ,

Total payment required @ A\$0.15 per Option

A\$    ,    ,    .

**Important:** When calculating the dollar amount payable, holders must round up the amount payable to nearest cent.

### 2. Payment: You can pay either by BPAY or Electronic Funds Transfer (EFT)

#### Option A – BPAY



**Biller Code:**

**Ref:**

Mobile & Internet Banking – BPAY®  
Make this payment from your cheque or savings account.

You should check the processing cut-off time for BPAY transactions with your bank, credit union or building society to ensure your payment will be received by the Share Registry in time.

**Note: Please ensure you use the BPAY details stated above as they are unique for each holding. You do not need to return this form if you have made payment via BPAY. Your BPAY reference number or unique reference number will process**

#### Option B – Electronic Funds Transfer (EFT)

Funds are to be deposited in AUD currency directly to following bank account:

**Account name:**

**Account BSB:**

**Account number:**

**Swift Code:**

**Your unique reference number:**

**IMPORTANT:** You must quote your **unique reference number** as your payment reference/description when processing your EFT payment. Failure to do so may result in your funds not being allocated to exercise the Options and Shares subsequently not issued.

**Note: You do not need to return this form if you have made payment via EFT. Your unique reference number will process your payment to you Options exercise electronically.**

### 3. Elect to receive communications electronically

If you have received this form by post, you have not provided your email address or elected to receive all communications electronically.

**We encourage you to elect to receive shareholder communications electronically to:**

- Help the Company reduce its printing and mailing costs.
- Receive investor communications faster and more securely.
- Help the environment through the need for less paper.

**SCAN THE QR CODE TO VISIT**  
[HTTPS://INVESTOR.AUTOMIC.COM.AU](https://investor.automic.com.au)  
**AND UPDATE YOUR COMMUNICATION PREFERENCE**



If you have any queries, please contact Automic on 1300 288 664 (within Australia) or +61 2 9698 5414 (international) between 8.30am and 7.00pm (Sydney time), Monday to Friday or email [corporate.actions@automicgroup.com.au](mailto:corporate.actions@automicgroup.com.au).